Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6325032 | 0.99 | F10 (0.42) | F10PRSS1TNFMEN1KMT2A | |
| SCHEMBL2995351 | 0.79 | L3MBTL1 (0.43) | F10PRSS1MEN1KMT2AGAA | |
| SCHEMBL2991625 | 0.77 | F10 (0.41) | F10PRSS1F2HPGDALDH1A1 | |
| SCHEMBL2995398 | 0.74 | CDK1 (0.42) | F10PRSS1HPGDALDH1A1LMNA | |
| SCHEMBL2998619 | 0.74 | F10 (0.46) | F10PRSS1F2HPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL6326771 | 0.74 | F10 (0.45) | F10PRSS1F2HPGDALDH1A1 | |
| SCHEMBL6324686 | 0.73 | F10 (0.46) | F10PRSS1F2HPGDALDH1A1 | |
| SCHEMBL6324682 | 0.72 | SLC6A9 (0.43) | MEN1KMT2AHPGDALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL6325009 | 0.72 | HPGD (0.43) | F10PRSS1MEN1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL6323212 | 0.72 | F10 (0.45) | F10PRSS1F2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | claimed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | claimed |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | disclosed |
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | EISERT WOLFGANG | 2009-02-19 | — | — | US | disclosed |
| EP-1885354-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | Boehringer Ingelheim International GmbH (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1747016-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103206-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005113006-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
| US-6838421-B2 | Bathroom cleaning composition | COLGATE-PALMOLIVE COMPANY (US) | 2005-01-04 | — | — | US | disclosed |
| WO-2004080970-A1 | NOVEL BICYCLIC AROMATIC COMPOUNDS, THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | ANXA5, F5, ANXA3 | F10 112/4885PRSS1 333/4885TNF 1923/4885 |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | PEPD, PLAT, TFPI | F10 51/4885PRSS1 109/4885TNF 1539/4885 |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | PROC, F12, SERPINC1 | F10 6/4885PRSS1 158/4885TNF 2793/4885 |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | F12, F2, F11 | F10 11/4885PRSS1 182/4885TNF 3132/4885 |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | PROC, F12, SERPINC1 | F10 6/4885PRSS1 158/4885TNF 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.